Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  KOREA EXCHANGE (KOSDAQ)  >  Seegene Inc    A096530   KR7096530001

SEEGENE INC

(A096530)
  Report
 SummaryNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Financials
Sales 2020 985 B 0,87 B 0,87 B
Net income 2020 475 B 0,42 B 0,42 B
Net cash position 2020 359 B 0,32 B 0,32 B
P/E ratio 2020 14,2x
Yield 2020 0,04%
Sales 2021 994 B 0,88 B 0,88 B
Net income 2021 443 B 0,39 B 0,39 B
Net cash position 2021 810 B 0,72 B 0,72 B
P/E ratio 2021 15,2x
Yield 2021 0,08%
Capitalization 6 662 B 5 903 M 5 909 M
EV / Sales 2020 6 761x
EV / Sales 2021 6 704x
Nbr of Employees 216
Free-Float 66,9%
More Financials
Company
Seegene, Inc. is a Korea-based company engaged in the development, manufacturing and distribution of molecular diagnostic reagents. The Company mainly provides infectious pathogens inspection products, including allergic respiratory pathogens, sexually transmitted diseases pathogens, human papilloma virus (HPV) and other inspection products, drug resistance inspection products, single nucleotide polymorphisms (SNP)... 
More about the company
Notations Surperformance© of Seegene Inc
Trading Rating : Investor Rating :
More Ratings
All news about SEEGENE INC
09/16Hyundai's U.S. Actions in Response to Coronavirus (COVID-19)
AQ
09/08SEEGENE : introduces a High-throughput 8-plex Test for Flu A, Flu B, RSV and COV..
AQ
08/13SEEGENE : South Korean COVID-19 test kit maker Seegene posts second-quarter prof..
RE
07/13Hyundai's U.S. Actions in Response to Coronavirus (COVID-19)
AQ
06/04Hyundai's U.S. Actions in Response to Coronavirus (COVID-19)
AQ
05/27Hyundai's U.S. Actions in Response to Coronavirus (COVID-19)
AQ
05/18SEEGENE : Exports 10 million Corona Tests to Brazil
AQ
05/14Hyundai's U.S. Actions in Response to Coronavirus (COVID-19)
AQ
05/08Hyundai's U.S. Actions in Response to Coronavirus (COVID-19)
AQ
05/05Hyundai's U.S. Actions in Response to Coronavirus (COVID-19)
AQ
05/03COVID-19 : More testing kits desperately needed - NCDC
AQ
04/28COVID-19 : More testing kits desperately needed - NCDC
AQ
04/27Hyundai's U.S. Actions in Response to Coronavirus (COVID-19)
AQ
04/27QIAGEN N : COVID-19 - More Testing Kits Desperately Needed - NCDC
AQ
04/27QIAGEN N : Govt's Dilemma - Can Lockdown Ease Amidst Rising Deaths and Spread of..
AQ
More news
News in other languages on SEEGENE INC

- No features available -

More news
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 352 000,00 KRW
Last Close Price 256 300,00 KRW
Spread / Highest target 67,8%
Spread / Average Target 37,3%
Spread / Lowest Target 17,1%
EPS Revisions
Managers
NameTitle
Jong-Yoon Chun Chief Executive Officer & Director
Jung-Yong Kim Director & Head-Finance
Kyung-Jun Chun Director
Hong-Il Yoon Independent Director
Jin-Soo Choi Director & Vice President
Sector and Competitors
1st jan.Capitalization (M$)
SEEGENE INC5 903
EXACT SCIENCES CORPORATION41.78%16 003
GUARDANT HEALTH, INC.42.94%10 251
BGI GENOMICS CO., LTD.97.19%7 942
ADAPTIVE BIOTECHNOLOGIES CORPORATION71.19%6 783
INVITAE CORPORATION198.39%6 073